Quick Answer
GRI Bio, Inc. reported Stockholders Equity of $6.01 million for the year ending 2025.
- GRI Bio, Inc. showed an increase of +49.0% in Stockholders Equity from 2024 to 2025.
- This data is from GRI Bio, Inc.'s annual report (Form 10-K), filed with the SEC on January 30, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: $2.09 million | Q2 2020: $969.0 thousand | Q3 2020: -$24.0 thousand | Q1 2021: $12.03 million | Q2 2021: $9.85 million | Q3 2021: $8.73 million | Q1 2022: -$5.15 million | Q2 2022: -$5.45 million | Q3 2022: -$5.71 million | Q1 2023: -$3.23 million | Q2 2023: $4.04 million | Q3 2023: $2.23 million | Q1 2024: $2.80 million | Q2 2024: $4.72 million | Q3 2024: $3.66 million | Q1 2025: $1.21 million | Q2 2025: $3.32 million | Q3 2025: $1.99 million.
- Over the full 7 years of available data (2019 to 2025), GRI Bio, Inc.'s Stockholders Equity has grown by 86.9%.
- Historical annual values: Fiscal year 2025: $6.01 million | Fiscal year 2024: $4.03 million | Fiscal year 2023: $259.0 thousand | Fiscal year 2022: -$1.63 million | Fiscal year 2021: -$4.85 million | Fiscal year 2020: -$1.45 million | Fiscal year 2019: $3.21 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: